查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2101704

液態生物檢體市場報告：趨勢、預測和競爭分析（至2035年）

Liquid Biopsy Market Report: Trends, Forecast and Competitive Analysis to 2035
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

液態生物檢體市場

全球液態生物檢體市場前景廣闊，預計在合約實驗室、醫院和醫生檢查室以及學術和研究機構等市場都將迎來發展機會。全球液態生物檢體市場預計在2026年至2035年間以7.4%的複合年成長率成長，到2035年市場規模預計將達到123億美元。推動該市場成長的關鍵因素包括：精準醫療的日益普及帶來的市場擴張、對非侵入性診斷解決方案需求的成長以及液態生物檢體在監測治療進展方面的應用日益廣泛。

  • 根據 Lucintel 的預測，在預測期內，檢測試劑盒預計將在產品類型中呈現最高的成長率，這主要得益於準確快速檢測的需求不斷成長。
  • 按最終用途分類，由於醫院擴大採用液態生物檢體診斷技術，因此醫院和醫生檢查室的成長率預計將最高。
  • 從區域來看，受癌症發生率上升和診斷基礎設施擴張的推動，亞太地區預計將在預測期內呈現最高的成長率。

液態生物檢體市場的新趨勢

受技術進步、癌症發病率上升以及微創診斷方法普及的推動，液態生物檢體市場正經歷快速成長。隨著醫療機構對更精準、快速且微創的癌症檢測和監測方案的需求日益成長，市場也在不斷發展，湧現出創新解決方案並拓展應用範圍。這些進步不僅改善了患者的治療效果，也正在改變臨床工作流程和醫療經濟格局。以下關鍵趨勢凸顯了該市場的動態特性及其向個人化醫療和提高診斷準確性的發展軌跡。

  • 多重分析檢測的引入：此趨勢的特徵是將多種生物標記（例如循環腫瘤DNA (ctDNA)、循環性腫瘤細胞(CTC) 和外泌體）結合起來，以提高診斷準確性。多重分析檢測能夠全面揭示腫瘤異質性和抗藥性機制，從而實現更精準的治療決策。隨著技術的進步，檢查室現在可以同時檢測多種生物標記物，從而縮短檢測時間並提高靈敏度。預計這種方法將成為一項標準技術，並將液態生物檢體的應用範圍擴展到各種類型和階段的癌症。
  • 人工智慧 (AI) 與機器學習的融合：人工智慧和機器學習演算法正日益整合到液態生物檢體平台中，用於分析複雜的資料集。這些技術能夠提升對遺傳和分子訊息的解讀，辨識模式，並預測治療反應。人工智慧驅動的分析可提高診斷準確性，減少假陽性和假陰性，並有助於制定個人化的治療方案。人工智慧工具的進一步發展將實現即時數據分析，簡化工作流程，幫助臨床醫生做出更明智的決策，並最終改善患者的治療效果。
  • 應用範圍拓展至癌症之外：液態生物檢體最初專注於腫瘤學，如今正擴展到其他醫學領域，例如感染疾病、產前檢測和自體免疫疾病。例如，檢測血液樣本中的病毒DNA或RNA有助於診斷感染疾病，而胎兒DNA分析則提供了一種非侵入性的產前檢測方法。這種多元化拓展了市場範圍，增加了市場需求，並促進了檢測方法的創新。隨著研究的深入，液態生物檢體有望成為一種多功能工具，滿足癌症以外的各種診斷需求。
  • 伴隨診斷和個人化治療的發展：標靶治療的興起增加了對能夠識別特定基因突變的伴隨診斷的需求。液態生物檢體擴大用於確定患者的最佳個體化治療方案、監測治療效果以及早期檢測抗藥性突變。這一趨勢推動了精準醫療的發展，並實現了能夠提高療效、減少副作用的個人化治療。液態生物檢體在臨床工作流程中用於治療選擇和監測的整合預計將會加速，從而促進診斷行業和製藥行業之間更緊密的合作。
  • 法規核准與標準化工作：隨著液態生物檢體技術的日趨成熟，監管機構正在製定檢驗、批准和臨床應用指南。檢體採集、處理和分析方法的標準化對於確保檢查室的可重複性和可靠性至關重要。近期針對某些癌症的液態生物檢體檢測獲得批准，正在增強市場信心並促進其應用。持續推動國際標準和法律規範的製定，將有助於液體活體組織切片技術的更廣泛接受、醫保覆蓋以及融入常規臨床實踐，最終推動市場成長和創新。

這些新趨勢正透過提高診斷準確性、拓展應用領域以及整合先進技術，重塑液態生物檢體市場。它們加速了向個人化、微創和快速診斷的轉變，這將對患者照護、臨床工作流程以及整個醫療保健行業產生重大影響。

液態生物檢體市場的最新趨勢

受技術進步、癌症發病率上升以及微創診斷方法普及的推動，液態生物檢體市場正經歷快速成長。這些發展正在透過實現疾病早期檢測、個人化治療和即時監測來變革醫療保健。隨著市場的演變，關鍵創新和策略聯盟正在拓展其在各個醫療保健領域的應用範圍，預計將改善患者預後並提供更具成本效益的醫療解決方案。這種充滿活力的市場環境為相關人員提供了把握新興趨勢和技術突破的巨大機會。

  • 癌症發生率上升：全球癌症發生率的不斷攀升是推動液態生物檢體技術普及的主要動力，因為早期發現和監測對於有效治療至關重要。液態生物檢體是一種微創的替代傳統組織切片檢查的方法，能夠實現更頻繁的檢查，並即時了解腫瘤動態。這一成長機會正在擴大市場，吸引投資，並促進研發更靈敏、更特異的診斷工具。因此，醫療機構能夠改善患者管理和治療效果，從而進一步推動市場成長。
  • 檢測方法的技術進步：數位PCR和次世代定序（NGS）等創新技術顯著提高了液態生物檢體的靈敏度和準確性。這些進步使得對低濃度生物標記和基因突變的精準檢測成為可能。隨著技術的進步，檢測成本不斷降低，液態生物檢體的應用範圍，包括癌症早期檢測、微量殘存疾病監測和治療抗藥性評估，加速了市場成長和普及。
  • 個人化醫療領域應用日益廣泛：液態生物檢體透過提供腫瘤的詳細基因圖譜，協助制定個人化治療策略。這使得臨床醫生能夠選擇標靶治療、監測治療反應並快速調整治療方案。個人化醫療的興起推動了對液態生物檢體檢測的需求，尤其是在腫瘤學領域。隨著醫療系統逐漸認知到個人化治療方案的優勢，預計市場將顯著成長，各公司正加大投入，開發綜合檢測組合和伴隨診斷產品，以滿足臨床需求。
  • 人們對早期診斷和疾病監測的興趣日益濃厚：液態生物檢體能夠早期發現癌症並即時監測疾病進展，從而革新患者照護。早期診斷可提高存活率，而持續監測則有助於評估治療效果並檢測復發。這種日益成長的興趣正在推動相關研究、法規核准、臨床應用拓展以及在醫療機構中的普及。因此，市場正在快速擴張，旨在早期檢測和持續疾病管理的檢測方法和平台數量也在增加。
  • 策略聯盟與法規核准：生物技術公司、製藥公司和醫療服務提供者之間的合作正在加速液態生物檢體產品的創新和商業化。法規核准的增加提高了產品的信譽度，並促進了市場准入。這些聯盟有助於開發先進的診斷工具，拓展通路，並加速臨床檢驗。因此，市場競爭日益激烈，充滿活力，吸引了更多投資，推動液態生物檢體融入標準治療方案，並促進了市場的進一步成長。

這些趨勢的總體影響是形成了一個快速擴張的液態生物檢體市場，其特點是技術創新、臨床應用日益普及和應用範圍不斷擴大。這些因素正在提高診斷準確性，實現個人化治療，並降低醫療成本。因此，預計該市場將持續成長，為相關人員帶來重大機遇，並改變全球疾病管理的模式。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景與分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章：全球液態生物檢體市場：依產品分類

  • 吸引力分析：按產品
  • 檢測試劑盒
  • 裝置
  • 服務

第5章：全球液態生物檢體市場：按循環生物標記分類

  • 吸引力分析：透過循環生物標記
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 無細胞DNA
  • 細胞外囊泡
  • 其他

第6章 全球液態生物檢體市場：依應用領域分類

  • 吸引力分析：依目的
  • 腫瘤學
  • 非癌症

第7章：全球液態生物檢體市場：依最終用途分類

  • 吸引力分析：依最終用途分類
  • 參考實驗室
  • 醫院和醫生檢查室
  • 學術和研究機構
  • 其他

第8章 區域分析

第9章：北美液態生物檢體市場

  • 北美液態生物檢體市場：按產品分類
  • 北美液態生物檢體市場：按最終用途分類
  • 美國液態生物檢體市場
  • 加拿大液態生物檢體市場
  • 墨西哥液態生物檢體市場

第10章：歐洲液態生物檢體市場

  • 歐洲液態生物檢體市場：依產品分類
  • 歐洲液態生物檢體市場：按最終用途分類
  • 德國液態生物檢體市場
  • 法國液態生物檢體市場
  • 義大利液態生物檢體市場
  • 西班牙液態生物檢體市場
  • 英國液態生物檢體市場

第11章：亞太地區的液態生物檢體市場

  • 亞太地區液態生物檢體市場：依產品分類
  • 亞太地區液態生物檢體市場：按最終用途分類
  • 中國的液態生物檢體市場
  • 印度液態生物檢體市場
  • 日本液態生物檢體市場
  • 韓國液態生物檢體市場
  • 印尼液態生物檢體市場

第12章：世界其他地區的液態生物檢體市場

  • 其他地區的液態生物檢體市場：按產品分類
  • 其他地區的液態生物檢體市場：按最終用途分類
  • 中東液態生物檢體市場
  • 南美洲液態生物檢體市場
  • 非洲液態生物檢體市場

第13章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第14章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 新趨勢：全球液態生物檢體市場
  • 戰略分析

第15章：價值鏈關鍵企業的企業概況

  • 競爭分析概述
  • Bio-Rad Laboratories
  • QIAGEN
  • MDxHealth
  • Myriad Genetics
  • Biocept, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Cardiff Oncology
  • Guardant Health

第16章附錄

Liquid Biopsy Market

The future of the global liquid biopsy market looks promising with opportunities in the reference laboratory, hospital & physician laboratory, and academic & research center markets. The global liquid biopsy market is expected to reach an estimated $12.3 billion by 2035 with a CAGR of 7.4% from 2026 to 2035. The major drivers for this market are the increasing use of precision medicine is driving market expansion, the rising need for non-invasive diagnosis solution, and the growing use of liquid biopsy in treatment monitoring.

  • Lucintel forecasts that, within the product category, assay kit is expected to witness the highest growth over the forecast period due to the increasing demand for accurate and rapid testing.
  • Within the end use category, hospital & physician laboratory is expected to witness the highest growth due to the growing adoption of liquid biopsy diagnostics in hospitals.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the rising cancer prevalence and expanding diagnostic infrastructure.

Emerging Trends in Liquid Biopsy Market

The liquid biopsy market is experiencing rapid growth driven by technological advancements, increasing cancer prevalence, and a shift towards minimally invasive diagnostic methods. As healthcare providers seek more accurate, faster, and less invasive options for cancer detection and monitoring, the market is evolving with innovative solutions and expanding applications. These developments are not only improving patient outcomes but also transforming clinical workflows and healthcare economics. The following key trends highlight the dynamic nature of this market and its trajectory toward personalized medicine and improved diagnostic precision.

  • Adoption of Multi-Analyte Testing: This trend involves combining various biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes to enhance diagnostic accuracy. Multi-analyte testing provides comprehensive insights into tumor heterogeneity and resistance mechanisms, enabling more precise treatment decisions. As technology advances, labs can detect multiple biomarkers simultaneously, reducing turnaround times and improving sensitivity. This approach is expected to become standard practice, broadening the scope of liquid biopsy applications across different cancer types and stages.
  • Integration of Artificial Intelligence (AI) and Machine Learning: AI and machine learning algorithms are increasingly being integrated into liquid biopsy platforms to analyze complex data sets. These technologies improve the interpretation of genetic and molecular information, identify patterns, and predict treatment responses. AI-driven analytics enhance diagnostic accuracy, reduce false positives/negatives, and facilitate personalized treatment planning. As AI tools become more sophisticated, they will enable real-time data analysis, streamline workflows, and support clinicians in making more informed decisions, ultimately improving patient outcomes.
  • Expansion Into Non-Cancer Applications: While initially focused on oncology, liquid biopsy is now expanding into other medical fields such as infectious diseases, prenatal testing, and autoimmune disorders. For example, detecting viral DNA or RNA in blood samples can aid in diagnosing infections, while fetal DNA analysis offers non-invasive prenatal testing options. This diversification broadens the market scope, increases demand, and encourages innovation in assay development. As research progresses, liquid biopsy could become a versatile tool for various diagnostic needs beyond cancer.
  • Development of Companion Diagnostics and Personalized Therapies: The rise of targeted therapies has driven the need for companion diagnostics that identify specific genetic mutations. Liquid biopsies are increasingly used to match patients with personalized treatment regimens, monitor therapeutic efficacy, and detect resistance mutations early. This trend supports the shift toward precision medicine, enabling tailored treatments that improve efficacy and reduce side effects. The integration of liquid biopsy into clinical workflows for therapy selection and monitoring is expected to accelerate, fostering closer collaboration between diagnostic and pharmaceutical industries.
  • Regulatory Approvals and Standardization Efforts: As liquid biopsy technologies mature, regulatory agencies are establishing guidelines for validation, approval, and clinical use. Standardization of sample collection, processing, and analysis methods is critical to ensure reproducibility and reliability across laboratories. Recent approvals of liquid biopsy tests for specific cancers have increased market confidence and adoption. Ongoing efforts to develop international standards and regulatory frameworks will facilitate broader acceptance, reimbursement, and integration into routine clinical practice, ultimately driving market growth and innovation.

These emerging trends are reshaping the liquid biopsy market by enhancing diagnostic accuracy, expanding application areas, and integrating advanced technologies. They are fostering a shift toward personalized, minimally invasive, and rapid diagnostics, which will significantly impact patient care, clinical workflows, and the overall healthcare landscape.

Recent Developments in the Liquid Biopsy Market

The liquid biopsy market is experiencing rapid growth driven by technological advancements, increasing cancer prevalence, and a shift towards minimally invasive diagnostic methods. These developments are transforming healthcare by enabling early detection, personalized treatment, and real-time monitoring of diseases. As the market evolves, key innovations and strategic collaborations are expanding its applications across various medical fields, promising improved patient outcomes and cost-effective healthcare solutions. This dynamic environment presents significant opportunities for stakeholders to capitalize on emerging trends and technological breakthroughs.

  • Growing Cancer Prevalence: The rising incidence of cancer worldwide is a primary driver for liquid biopsy adoption, as early detection and monitoring are crucial for effective treatment. Liquid biopsies offer a minimally invasive alternative to traditional tissue biopsies, enabling frequent testing and real-time insights into tumor dynamics. This growth opportunity is expanding the market, attracting investments, and encouraging research to develop more sensitive and specific diagnostic tools. Consequently, healthcare providers can improve patient management and treatment outcomes, fueling market expansion.
  • Technological Advancements in Detection Methods: Innovations such as digital PCR and next-generation sequencing (NGS) have significantly enhanced the sensitivity and accuracy of liquid biopsies. These advancements allow for the detection of low-abundance biomarkers and genetic mutations with high precision. As technology continues to evolve, the cost of testing decreases, making liquid biopsies more accessible. This progress is broadening the scope of applications, including early cancer detection, minimal residual disease monitoring, and therapy resistance assessment, thereby accelerating market growth and adoption.
  • Increasing Adoption in Personalized Medicine: Liquid biopsies facilitate tailored treatment strategies by providing detailed genetic profiles of tumors. This enables clinicians to select targeted therapies, monitor treatment response, and adjust regimens promptly. The shift towards personalized medicine is boosting demand for liquid biopsy tests, especially in oncology. As healthcare systems recognize the benefits of individualized treatment plans, the market is poised for substantial growth, with companies investing in developing comprehensive panels and companion diagnostics to meet clinical needs.
  • Rising Focus on Early Diagnosis and Disease Monitoring: The ability of liquid biopsies to detect cancer at early stages and monitor disease progression in real-time is transforming patient care. Early diagnosis improves survival rates, while ongoing monitoring helps in assessing treatment efficacy and detecting relapse. This focus is driving research and regulatory approvals, expanding clinical applications, and increasing adoption across healthcare settings. Consequently, the market is experiencing rapid expansion, with a growing number of tests and platforms designed for early detection and continuous disease management.
  • Strategic Collaborations and Regulatory Approvals: Partnerships between biotech firms, pharmaceutical companies, and healthcare providers are accelerating innovation and commercialization of liquid biopsy products. Regulatory approvals are also increasing, providing credibility and facilitating market entry. These collaborations enable the development of advanced diagnostic tools, expand distribution channels, and foster clinical validation. As a result, the market is becoming more competitive and dynamic, attracting investments and encouraging the integration of liquid biopsies into standard care protocols, further propelling growth.

The overall impact of these developments is a rapidly expanding liquid biopsy market characterized by technological innovation, increased clinical adoption, and broader application scope. These factors are improving diagnostic accuracy, enabling personalized treatment, and reducing healthcare costs. As a result, the market is poised for sustained growth, offering significant opportunities for stakeholders and transforming disease management paradigms worldwide.

Strategic Growth Opportunities in the Liquid Biopsy Market

The liquid biopsy market is experiencing rapid expansion driven by technological advancements, increasing cancer prevalence, and demand for minimally invasive diagnostic tools. This growth presents numerous opportunities for innovation, strategic partnerships, and market penetration across various healthcare sectors. Companies that leverage these opportunities can enhance diagnostic accuracy, improve patient outcomes, and gain competitive advantages in a dynamic and evolving landscape. Understanding these key growth areas is essential for stakeholders aiming to capitalize on the market's potential.

  • Expansion Into Personalized Medicine Through Liquid Biopsy: The integration of liquid biopsy into personalized treatment plans offers significant growth potential. By enabling real-time monitoring of tumor genetics, clinicians can tailor therapies more effectively, leading to improved patient outcomes. Advances in genomic profiling and biomarker discovery are facilitating this shift, encouraging pharmaceutical collaborations and research investments. As precision medicine gains traction, the demand for liquid biopsy solutions that support individualized treatment strategies is expected to surge, creating new revenue streams and market segments.
  • Increasing Adoption in Early Cancer Detection and Screening: Liquid biopsy's non-invasive nature makes it ideal for early cancer detection and screening programs. Its ability to identify circulating tumor DNA (ctDNA) at early stages can lead to earlier interventions, reducing mortality rates. Growing awareness, regulatory approvals, and technological improvements are driving adoption across healthcare systems worldwide. This opportunity is particularly relevant for high-risk populations, where regular screening can significantly impact disease prognosis, thereby expanding the market and encouraging new product development.
  • Technological Advancements in Assay Sensitivity and Specificity: Continuous innovation in assay technologies enhances the sensitivity and specificity of liquid biopsy tests. Improved detection of low-abundance biomarkers and reduction of false positives are critical for clinical reliability. These advancements enable broader application in various cancers and other diseases, fostering confidence among clinicians and patients. Investment in novel platforms, such as digital PCR and next-generation sequencing, is expected to further refine diagnostic accuracy, opening avenues for regulatory approvals and commercialization of next-generation liquid biopsy products.
  • Strategic Collaborations and Partnerships To Accelerate Market Growth: Collaborations between biotech firms, pharmaceutical companies, and healthcare providers are vital for expanding market reach. These partnerships facilitate technology sharing, clinical validation, and regulatory navigation, accelerating product development and commercialization. Joint ventures can also enhance access to new markets and customer bases. As the market matures, strategic alliances will be crucial for integrating liquid biopsy into standard care protocols, fostering innovation, and driving revenue growth through combined expertise and resources.
  • Growing Demand for Liquid Biopsy in Monitoring Treatment Response and Resistance: The ability to monitor tumor dynamics in real-time offers significant clinical value. Liquid biopsy enables tracking of treatment efficacy and early detection of resistance mutations, allowing timely adjustments to therapy. This ongoing surveillance improves patient management and reduces unnecessary treatments. As targeted therapies become more prevalent, the need for dynamic monitoring tools will increase, creating opportunities for developing advanced assays and expanding the clinical utility of liquid biopsy in ongoing disease management.

The overall impact of these opportunities is poised to significantly accelerate market growth, foster innovation, and improve patient care. Companies that strategically invest in these areas will be well-positioned to capitalize on emerging trends, expand their market share, and contribute to the evolution of cancer diagnostics and treatment. This dynamic landscape promises substantial benefits for healthcare providers, patients, and industry stakeholders alike.

Liquid Biopsy Market Drivers and Challenges

The liquid biopsy market is influenced by a range of technological, economic, and regulatory factors that shape its growth trajectory. Advances in molecular diagnostics and personalized medicine are driving innovation, while increasing healthcare expenditure and demand for minimally invasive procedures are expanding market opportunities. Regulatory approvals and reimbursement policies also play a crucial role in market development. However, challenges such as high costs, lack of standardization, and regulatory hurdles pose significant barriers. Understanding these drivers and challenges is essential for stakeholders to navigate the evolving landscape and capitalize on emerging opportunities in this dynamic sector.

The factors responsible for driving the liquid biopsy market include:-

  • Technological Advancements: The rapid development of sensitive detection techniques like next-generation sequencing (NGS) and digital PCR has significantly improved the accuracy and reliability of liquid biopsies. These innovations enable early detection of cancer and real-time monitoring of treatment response, fostering confidence among clinicians and patients. As technology continues to evolve, costs are decreasing, making liquid biopsies more accessible. This progress supports the shift toward personalized medicine, where tailored treatments improve patient outcomes and reduce healthcare costs, thereby fueling market growth.
  • Rising Incidence of Cancer: The increasing prevalence of cancer worldwide, driven by aging populations, lifestyle factors, and environmental exposures, is a major market driver. Early detection and monitoring are critical for effective treatment, and liquid biopsies offer a minimally invasive alternative to traditional tissue biopsies. The ability to detect circulating tumor DNA (ctDNA) and other biomarkers in blood samples facilitates early diagnosis, prognosis, and treatment customization. As cancer cases continue to rise, demand for liquid biopsy solutions is expected to grow substantially, expanding market opportunities across regions.
  • Growing Adoption of Personalized Medicine: The shift toward personalized treatment strategies is a key factor propelling the liquid biopsy market. By providing molecular insights into tumor genetics, liquid biopsies enable clinicians to select targeted therapies and monitor their effectiveness. This approach reduces unnecessary treatments and associated side effects, improving patient quality of life. The increasing acceptance of precision medicine in oncology and other therapeutic areas encourages healthcare providers and payers to adopt liquid biopsy techniques, thereby expanding their use and driving market expansion.
  • Favorable Regulatory Environment and Reimbursement Policies: Regulatory approvals from agencies such as the FDA and EMA have validated the clinical utility of liquid biopsy tests, boosting market confidence. Additionally, reimbursement policies are gradually evolving to cover these minimally invasive diagnostics, making them more accessible to patients. Supportive regulatory frameworks and reimbursement schemes incentivize healthcare providers to incorporate liquid biopsies into routine clinical practice, accelerating adoption and market growth. Continued policy development is expected to further facilitate market expansion.
  • Strategic Collaborations and Investments: The market is witnessing increased collaborations between biotech firms, pharmaceutical companies, and research institutions to develop innovative liquid biopsy products. Investments in R&D are fueling technological advancements and expanding the test portfolio. These partnerships also facilitate clinical validation and regulatory approval processes, reducing time-to-market. Such strategic alliances enhance market credibility and foster innovation, ultimately broadening the application scope and accelerating growth in the liquid biopsy sector.

The challenges in the liquid biopsy market are:

  • High Costs and Limited Reimbursement: Despite technological advancements, the high cost of liquid biopsy tests remains a significant barrier, especially in low- and middle-income countries. Limited reimbursement policies further restrict patient access and hinder widespread adoption. The lack of standardized pricing and coverage policies creates uncertainty for healthcare providers and payers, slowing market growth. Addressing cost issues and establishing comprehensive reimbursement frameworks are essential to ensure broader accessibility and to sustain market expansion.
  • Lack of Standardization and Validation: Variability in test performance, lack of standardized protocols, and limited clinical validation pose challenges to clinical adoption. Inconsistent results can undermine clinician confidence and delay regulatory approval processes. The absence of universally accepted guidelines hampers the integration of liquid biopsies into routine practice. Overcoming these issues requires extensive validation studies, consensus on testing procedures, and regulatory harmonization to ensure reliability and facilitate market growth.
  • Regulatory and Ethical Challenges: Navigating complex regulatory pathways and ensuring compliance with evolving standards is a significant hurdle. Additionally, ethical concerns related to genetic data privacy, informed consent, and potential misuse of information pose risks. Regulatory uncertainty can delay product approvals and market entry. Addressing these challenges necessitates clear regulatory frameworks, robust data protection measures, and stakeholder engagement to build trust and promote responsible innovation in the liquid biopsy domain.

The liquid biopsy market is driven by technological innovations, rising cancer incidence, personalized medicine adoption, supportive policies, and strategic collaborations. However, high costs, lack of standardization, and regulatory complexities present notable challenges. These factors collectively influence the pace and scope of market growth. Overcoming barriers and leveraging drivers will be crucial for stakeholders aiming to expand access, improve diagnostic accuracy, and realize the full potential of liquid biopsies in clinical practice. The market's future depends on balancing innovation with regulatory and economic considerations to ensure sustainable growth and improved patient outcomes.

List of Liquid Biopsy Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies liquid biopsy market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liquid biopsy market companies profiled in this report include-

  • Bio-Rad Laboratories
  • QIAGEN
  • MDxHealth
  • Myriad Genetics
  • Biocept, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Cardiff Oncology
  • Guardant Health

Liquid Biopsy Market by Segment

The study includes a forecast for the global liquid biopsy market by product, circulating biomarker, application, end use, and region.

Liquid Biopsy Market by Product [Value ($B) from 2019 to 2035]:

  • Assays Kits
  • Instruments
  • Services

Liquid Biopsy Market by Circulating Biomarker [Value ($B) from 2019 to 2035]:

  • Circulating Tumor Cells
  • Circulating Tumor DNA
  • Cell-Free DNA
  • Extracellular Vesicles
  • Others

Liquid Biopsy Market by Application [Value ($B) from 2019 to 2035]:

  • Oncology
  • Non-Cancer

Liquid Biopsy Market by End Use [Value ($B) from 2019 to 2035]:

  • Reference Laboratories
  • Hospitals & Physician Laboratories
  • Academic & Research Centers
  • Others

Liquid Biopsy Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Liquid Biopsy Market

The liquid biopsy market has experienced rapid growth driven by technological advancements, increasing adoption in clinical settings, and a rising prevalence of cancer worldwide. As healthcare systems evolve, countries are investing in innovative diagnostic tools to improve early detection, personalized treatment, and patient outcomes. Regulatory approvals and increased research funding further propel this sector forward. Each country's unique healthcare infrastructure, research capabilities, and market demands influence their development trajectory. Understanding these regional differences is crucial for stakeholders aiming to capitalize on emerging opportunities in the liquid biopsy landscape.

  • United States: The US leads the liquid biopsy market with significant technological innovations and high adoption rates. Major companies are developing advanced platforms for early cancer detection and monitoring. Regulatory agencies like the FDA have approved several liquid biopsy tests, boosting clinical integration. The focus is on personalized medicine, with extensive research funding supporting new biomarker discoveries. The healthcare infrastructure and reimbursement policies favor widespread adoption, making the US a key driver of market growth.
  • China: China is rapidly expanding its liquid biopsy market, driven by a large patient population and government initiatives to enhance cancer diagnostics. Local companies are developing cost-effective solutions tailored to regional needs. Increasing investments in biotech research and collaborations with international firms accelerate innovation. Regulatory frameworks are evolving to facilitate faster approval processes. The market is also benefiting from rising awareness and demand for minimally invasive diagnostic options, positioning China as a significant emerging player.
  • Germany: Germany's market growth is supported by a strong healthcare system and a focus on precision medicine. Leading biotech firms and research institutions are advancing liquid biopsy technologies for cancer management. Regulatory approval processes are streamlined, encouraging innovation. The country emphasizes clinical validation and integration into standard care protocols. Investments in research and development, along with collaborations across Europe, bolster Germany's position as a key market for advanced liquid biopsy solutions.
  • India: India's liquid biopsy market is in its nascent stages but shows promising growth potential. The increasing burden of cancer and rising awareness are driving demand for early detection tools. Local startups and international companies are introducing affordable, scalable solutions suitable for the Indian population. Government initiatives to improve healthcare infrastructure and promote biotech innovation support market expansion. Challenges include regulatory hurdles and limited reimbursement, but ongoing efforts aim to address these barriers and foster market development.
  • Japan: Japan's market is characterized by high technological adoption and a focus on innovative healthcare solutions. Leading companies are developing highly sensitive liquid biopsy tests for various cancers. The government's support for precision medicine and aging population drives demand for early diagnostic tools. Regulatory pathways are well-established, facilitating product approvals. Collaborations between academia and industry enhance research and development. Japan's emphasis on quality and innovation positions it as a mature and competitive market in the liquid biopsy sector.

Features of the Global Liquid Biopsy Market

  • Market Size Estimates: liquid biopsy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
  • Segmentation Analysis: liquid biopsy market size by various segments, such as by product, circulating biomarker, application, end use, and region in terms of value ($B).
  • Regional Analysis: liquid biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different product, circulating biomarker, application, end use, and regions for the liquid biopsy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the liquid biopsy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the liquid biopsy market by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles, and others), application (oncology and non-cancer), end use (reference laboratories, hospitals & physician laboratories, academic & research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Liquid Biopsy Market by Product

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Product
  • 4.3 Assays Kits : Trends and Forecast (2019 to 2035)
  • 4.4 Instruments : Trends and Forecast (2019 to 2035)
  • 4.5 Services : Trends and Forecast (2019 to 2035)

5. Global Liquid Biopsy Market by Circulating Biomarker

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Circulating Biomarker
  • 5.3 Circulating Tumor Cells : Trends and Forecast (2019 to 2035)
  • 5.4 Circulating Tumor DNA : Trends and Forecast (2019 to 2035)
  • 5.5 Cell-Free DNA : Trends and Forecast (2019 to 2035)
  • 5.6 Extracellular Vesicles : Trends and Forecast (2019 to 2035)
  • 5.7 Others : Trends and Forecast (2019 to 2035)

6. Global Liquid Biopsy Market by Application

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by Application
  • 6.3 Oncology : Trends and Forecast (2019 to 2035)
  • 6.4 Non-Cancer : Trends and Forecast (2019 to 2035)

7. Global Liquid Biopsy Market by End Use

  • 7.1 Overview
  • 7.2 Attractiveness Analysis by End Use
  • 7.3 Reference Laboratories : Trends and Forecast (2019 to 2035)
  • 7.4 Hospitals & Physician Laboratories : Trends and Forecast (2019 to 2035)
  • 7.5 Academic & Research Centers : Trends and Forecast (2019 to 2035)
  • 7.6 Others : Trends and Forecast (2019 to 2035)

8. Regional Analysis

  • 8.1 Overview
  • 8.2 Global Liquid Biopsy Market by Region

9. North American Liquid Biopsy Market

  • 9.1 Overview
  • 9.2 North American Liquid Biopsy Market by Product
  • 9.3 North American Liquid Biopsy Market by End Use
  • 9.4 The United States Liquid Biopsy Market
  • 9.5 Canadian Liquid Biopsy Market
  • 9.6 Mexican Liquid Biopsy Market

10. European Liquid Biopsy Market

  • 10.1 Overview
  • 10.2 European Liquid Biopsy Market by Product
  • 10.3 European Liquid Biopsy Market by End Use
  • 10.4 German Liquid Biopsy Market
  • 10.5 French Liquid Biopsy Market
  • 10.6 Italian Liquid Biopsy Market
  • 10.7 Spanish Liquid Biopsy Market
  • 10.8 The United Kingdom Liquid Biopsy Market

11. APAC Liquid Biopsy Market

  • 11.1 Overview
  • 11.2 APAC Liquid Biopsy Market by Product
  • 11.3 APAC Liquid Biopsy Market by End Use
  • 11.4 Chinese Liquid Biopsy Market
  • 11.5 Indian Liquid Biopsy Market
  • 11.6 Japanese Liquid Biopsy Market
  • 11.7 South Korean Liquid Biopsy Market
  • 11.8 Indonesian Liquid Biopsy Market

12. ROW Liquid Biopsy Market

  • 12.1 Overview
  • 12.2 ROW Liquid Biopsy Market by Product
  • 12.3 ROW Liquid Biopsy Market by End Use
  • 12.4 Middle Eastern Liquid Biopsy Market
  • 12.5 South American Liquid Biopsy Market
  • 12.6 African Liquid Biopsy Market

13. Competitor Analysis

  • 13.1 Product Portfolio Analysis
  • 13.2 Operational Integration
  • 13.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Growth Opportunity Analysis
    • 14.2.1 Growth Opportunity by Product
    • 14.2.2 Growth Opportunity by Circulating Biomarker
    • 14.2.3 Growth Opportunity by Application
    • 14.2.4 Growth Opportunity by End Use
    • 14.2.5 Growth Opportunity by Region
  • 14.3 Emerging Trends in the Global Liquid Biopsy Market
  • 14.4 Strategic Analysis
    • 14.4.1 New Product Development
    • 14.4.2 Certification and Licensing
    • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

  • 15.1 Competitive Analysis Overview
  • 15.2 Bio-Rad Laboratories
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.3 QIAGEN
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.4 MDxHealth
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.5 Myriad Genetics
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.6 Biocept, Inc.
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.7 F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.8 Thermo Fisher Scientific Inc.
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.9 Illumina, Inc.
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.10 Cardiff Oncology
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.11 Guardant Health
    • Company Overview
    • Liquid Biopsy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

16. Appendix

  • 16.1 List of Figures
  • 16.2 List of Tables
  • 16.3 Research Methodology
  • 16.4 Disclaimer
  • 16.5 Copyright
  • 16.6 Abbreviations and Technical Units
  • 16.7 About Us
  • 16.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Liquid Biopsy Market
  • Figure 2.1: Usage of Liquid Biopsy Market
  • Figure 2.2: Classification of the Global Liquid Biopsy Market
  • Figure 2.3: Supply Chain of the Global Liquid Biopsy Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the Liquid Biopsy Market
  • Figure 4.1: Global Liquid Biopsy Market by Product in 2019, 2025, and 2035
  • Figure 4.2: Trends of the Global Liquid Biopsy Market ($B) by Product
  • Figure 4.3: Forecast for the Global Liquid Biopsy Market ($B) by Product
  • Figure 4.4: Trends and Forecast for Assays Kits in the Global Liquid Biopsy Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Instruments in the Global Liquid Biopsy Market (2019-2035)
  • Figure 4.6: Trends and Forecast for Services in the Global Liquid Biopsy Market (2019-2035)
  • Figure 5.1: Global Liquid Biopsy Market by Circulating Biomarker in 2019, 2025, and 2035
  • Figure 5.2: Trends of the Global Liquid Biopsy Market ($B) by Circulating Biomarker
  • Figure 5.3: Forecast for the Global Liquid Biopsy Market ($B) by Circulating Biomarker
  • Figure 5.4: Trends and Forecast for Circulating Tumor Cells in the Global Liquid Biopsy Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Circulating Tumor DNA in the Global Liquid Biopsy Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Cell-Free DNA in the Global Liquid Biopsy Market (2019-2035)
  • Figure 5.7: Trends and Forecast for Extracellular Vesicles in the Global Liquid Biopsy Market (2019-2035)
  • Figure 5.8: Trends and Forecast for Others in the Global Liquid Biopsy Market (2019-2035)
  • Figure 6.1: Global Liquid Biopsy Market by Application in 2019, 2025, and 2035
  • Figure 6.2: Trends of the Global Liquid Biopsy Market ($B) by Application
  • Figure 6.3: Forecast for the Global Liquid Biopsy Market ($B) by Application
  • Figure 6.4: Trends and Forecast for Oncology in the Global Liquid Biopsy Market (2019-2035)
  • Figure 6.5: Trends and Forecast for Non-Cancer in the Global Liquid Biopsy Market (2019-2035)
  • Figure 7.1: Global Liquid Biopsy Market by End Use in 2019, 2025, and 2035
  • Figure 7.2: Trends of the Global Liquid Biopsy Market ($B) by End Use
  • Figure 7.3: Forecast for the Global Liquid Biopsy Market ($B) by End Use
  • Figure 7.4: Trends and Forecast for Reference Laboratories in the Global Liquid Biopsy Market (2019-2035)
  • Figure 7.5: Trends and Forecast for Hospitals & Physician Laboratories in the Global Liquid Biopsy Market (2019-2035)
  • Figure 7.6: Trends and Forecast for Academic & Research Centers in the Global Liquid Biopsy Market (2019-2035)
  • Figure 7.7: Trends and Forecast for Others in the Global Liquid Biopsy Market (2019-2035)
  • Figure 8.1: Trends of the Global Liquid Biopsy Market ($B) by Region (2019-2025)
  • Figure 8.2: Forecast for the Global Liquid Biopsy Market ($B) by Region (2026-2035)
  • Figure 9.1: Trends and Forecast for the North American Liquid Biopsy Market (2019-2035)
  • Figure 9.2: North American Liquid Biopsy Market by Product in 2019, 2025, and 2035
  • Figure 9.3: Trends of the North American Liquid Biopsy Market ($B) by Product (2019-2025)
  • Figure 9.4: Forecast for the North American Liquid Biopsy Market ($B) by Product (2026-2035)
  • Figure 9.5: North American Liquid Biopsy Market by Circulating Biomarker in 2019, 2025, and 2035
  • Figure 9.6: Trends of the North American Liquid Biopsy Market ($B) by Circulating Biomarker (2019-2025)
  • Figure 9.7: Forecast for the North American Liquid Biopsy Market ($B) by Circulating Biomarker (2026-2035)
  • Figure 9.8: Trends and Forecast for the United States Liquid Biopsy Market ($B) (2019-2035)
  • Figure 9.9: Trends and Forecast for the Mexican Liquid Biopsy Market ($B) (2019-2035)
  • Figure 9.10: Trends and Forecast for the Canadian Liquid Biopsy Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the European Liquid Biopsy Market (2019-2035)
  • Figure 10.2: European Liquid Biopsy Market by Product in 2019, 2025, and 2035
  • Figure 10.3: Trends of the European Liquid Biopsy Market ($B) by Product (2019-2025)
  • Figure 10.4: Forecast for the European Liquid Biopsy Market ($B) by Product (2026-2035)
  • Figure 10.5: European Liquid Biopsy Market by Circulating Biomarker in 2019, 2025, and 2035
  • Figure 10.6: Trends of the European Liquid Biopsy Market ($B) by Circulating Biomarker (2019-2025)
  • Figure 10.7: Forecast for the European Liquid Biopsy Market ($B) by Circulating Biomarker (2026-2035)
  • Figure 10.8: Trends and Forecast for the German Liquid Biopsy Market ($B) (2019-2035)
  • Figure 10.9: Trends and Forecast for the French Liquid Biopsy Market ($B) (2019-2035)
  • Figure 10.10: Trends and Forecast for the Spanish Liquid Biopsy Market ($B) (2019-2035)
  • Figure 10.11: Trends and Forecast for the Italian Liquid Biopsy Market ($B) (2019-2035)
  • Figure 10.12: Trends and Forecast for the United Kingdom Liquid Biopsy Market ($B) (2019-2035)
  • Figure 11.1: Trends and Forecast for the APAC Liquid Biopsy Market (2019-2035)
  • Figure 11.2: APAC Liquid Biopsy Market by Product in 2019, 2025, and 2035
  • Figure 11.3: Trends of the APAC Liquid Biopsy Market ($B) by Product (2019-2025)
  • Figure 11.4: Forecast for the APAC Liquid Biopsy Market ($B) by Product (2026-2035)
  • Figure 11.5: APAC Liquid Biopsy Market by Circulating Biomarker in 2019, 2025, and 2035
  • Figure 11.6: Trends of the APAC Liquid Biopsy Market ($B) by Circulating Biomarker (2019-2025)
  • Figure 11.7: Forecast for the APAC Liquid Biopsy Market ($B) by Circulating Biomarker (2026-2035)
  • Figure 11.8: Trends and Forecast for the Japanese Liquid Biopsy Market ($B) (2019-2035)
  • Figure 11.9: Trends and Forecast for the Indian Liquid Biopsy Market ($B) (2019-2035)
  • Figure 11.10: Trends and Forecast for the Chinese Liquid Biopsy Market ($B) (2019-2035)
  • Figure 11.11: Trends and Forecast for the South Korean Liquid Biopsy Market ($B) (2019-2035)
  • Figure 11.12: Trends and Forecast for the Indonesian Liquid Biopsy Market ($B) (2019-2035)
  • Figure 12.1: Trends and Forecast for the ROW Liquid Biopsy Market (2019-2035)
  • Figure 12.2: ROW Liquid Biopsy Market by Product in 2019, 2025, and 2035
  • Figure 12.3: Trends of the ROW Liquid Biopsy Market ($B) by Product (2019-2025)
  • Figure 12.4: Forecast for the ROW Liquid Biopsy Market ($B) by Product (2026-2035)
  • Figure 12.5: ROW Liquid Biopsy Market by Circulating Biomarker in 2019, 2025, and 2035
  • Figure 12.6: Trends of the ROW Liquid Biopsy Market ($B) by Circulating Biomarker (2019-2025)
  • Figure 12.7: Forecast for the ROW Liquid Biopsy Market ($B) by Circulating Biomarker (2026-2035)
  • Figure 12.8: Trends and Forecast for the Middle Eastern Liquid Biopsy Market ($B) (2019-2035)
  • Figure 12.9: Trends and Forecast for the South American Liquid Biopsy Market ($B) (2019-2035)
  • Figure 12.10: Trends and Forecast for the African Liquid Biopsy Market ($B) (2019-2035)
  • Figure 13.1: Porter's Five Forces Analysis of the Global Liquid Biopsy Market
  • Figure 13.2: Market Share (%) of Top Players in the Global Liquid Biopsy Market (2025)
  • Figure 14.1: Growth Opportunities for the Global Liquid Biopsy Market by Product
  • Figure 14.2: Growth Opportunities for the Global Liquid Biopsy Market by Circulating Biomarker
  • Figure 14.3: Growth Opportunities for the Global Liquid Biopsy Market by Application
  • Figure 14.4: Growth Opportunities for the Global Liquid Biopsy Market by End Use
  • Figure 14.5: Growth Opportunities for the Global Liquid Biopsy Market by Region
  • Figure 14.6: Emerging Trends in the Global Liquid Biopsy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2024-2025) and CAGR (%, 2026-2035) of the Liquid Biopsy Market by Product, Circulating Biomarker, Application, and End Use
  • Table 1.2: Attractiveness Analysis for the Liquid Biopsy Market by Region
  • Table 1.3: Global Liquid Biopsy Market Parameters and Attributes
  • Table 3.1: Trends of the Global Liquid Biopsy Market (2019-2025)
  • Table 3.2: Forecast for the Global Liquid Biopsy Market (2026-2035)
  • Table 4.1: Attractiveness Analysis for the Global Liquid Biopsy Market by Product
  • Table 4.2: Market Size and CAGR of Various Product in the Global Liquid Biopsy Market (2019-2025)
  • Table 4.3: Market Size and CAGR of Various Product in the Global Liquid Biopsy Market (2026-2035)
  • Table 4.4: Trends of Assays Kits in the Global Liquid Biopsy Market (2019-2025)
  • Table 4.5: Forecast for Assays Kits in the Global Liquid Biopsy Market (2026-2035)
  • Table 4.6: Trends of Instruments in the Global Liquid Biopsy Market (2019-2025)
  • Table 4.7: Forecast for Instruments in the Global Liquid Biopsy Market (2026-2035)
  • Table 4.8: Trends of Services in the Global Liquid Biopsy Market (2019-2025)
  • Table 4.9: Forecast for Services in the Global Liquid Biopsy Market (2026-2035)
  • Table 5.1: Attractiveness Analysis for the Global Liquid Biopsy Market by Circulating Biomarker
  • Table 5.2: Market Size and CAGR of Various Circulating Biomarker in the Global Liquid Biopsy Market (2019-2025)
  • Table 5.3: Market Size and CAGR of Various Circulating Biomarker in the Global Liquid Biopsy Market (2026-2035)
  • Table 5.4: Trends of Circulating Tumor Cells in the Global Liquid Biopsy Market (2019-2025)
  • Table 5.5: Forecast for Circulating Tumor Cells in the Global Liquid Biopsy Market (2026-2035)
  • Table 5.6: Trends of Circulating Tumor DNA in the Global Liquid Biopsy Market (2019-2025)
  • Table 5.7: Forecast for Circulating Tumor DNA in the Global Liquid Biopsy Market (2026-2035)
  • Table 5.8: Trends of Cell-Free DNA in the Global Liquid Biopsy Market (2019-2025)
  • Table 5.9: Forecast for Cell-Free DNA in the Global Liquid Biopsy Market (2026-2035)
  • Table 5.10: Trends of Extracellular Vesicles in the Global Liquid Biopsy Market (2019-2025)
  • Table 5.11: Forecast for Extracellular Vesicles in the Global Liquid Biopsy Market (2026-2035)
  • Table 5.12: Trends of Others in the Global Liquid Biopsy Market (2019-2025)
  • Table 5.13: Forecast for Others in the Global Liquid Biopsy Market (2026-2035)
  • Table 6.1: Attractiveness Analysis for the Global Liquid Biopsy Market by Application
  • Table 6.2: Market Size and CAGR of Various Application in the Global Liquid Biopsy Market (2019-2025)
  • Table 6.3: Market Size and CAGR of Various Application in the Global Liquid Biopsy Market (2026-2035)
  • Table 6.4: Trends of Oncology in the Global Liquid Biopsy Market (2019-2025)
  • Table 6.5: Forecast for Oncology in the Global Liquid Biopsy Market (2026-2035)
  • Table 6.6: Trends of Non-Cancer in the Global Liquid Biopsy Market (2019-2025)
  • Table 6.7: Forecast for Non-Cancer in the Global Liquid Biopsy Market (2026-2035)
  • Table 7.1: Attractiveness Analysis for the Global Liquid Biopsy Market by End Use
  • Table 7.2: Market Size and CAGR of Various End Use in the Global Liquid Biopsy Market (2019-2025)
  • Table 7.3: Market Size and CAGR of Various End Use in the Global Liquid Biopsy Market (2026-2035)
  • Table 7.4: Trends of Reference Laboratories in the Global Liquid Biopsy Market (2019-2025)
  • Table 7.5: Forecast for Reference Laboratories in the Global Liquid Biopsy Market (2026-2035)
  • Table 7.6: Trends of Hospitals & Physician Laboratories in the Global Liquid Biopsy Market (2019-2025)
  • Table 7.7: Forecast for Hospitals & Physician Laboratories in the Global Liquid Biopsy Market (2026-2035)
  • Table 7.8: Trends of Academic & Research Centers in the Global Liquid Biopsy Market (2019-2025)
  • Table 7.9: Forecast for Academic & Research Centers in the Global Liquid Biopsy Market (2026-2035)
  • Table 7.10: Trends of Others in the Global Liquid Biopsy Market (2019-2025)
  • Table 7.11: Forecast for Others in the Global Liquid Biopsy Market (2026-2035)
  • Table 8.1: Market Size and CAGR of Various Regions in the Global Liquid Biopsy Market (2019-2025)
  • Table 8.2: Market Size and CAGR of Various Regions in the Global Liquid Biopsy Market (2026-2035)
  • Table 9.1: Trends of the North American Liquid Biopsy Market (2019-2025)
  • Table 9.2: Forecast for the North American Liquid Biopsy Market (2026-2035)
  • Table 9.3: Market Size and CAGR of Various Product in the North American Liquid Biopsy Market (2019-2025)
  • Table 9.4: Market Size and CAGR of Various Product in the North American Liquid Biopsy Market (2026-2035)
  • Table 9.5: Market Size and CAGR of Various Circulating Biomarker in the North American Liquid Biopsy Market (2019-2025)
  • Table 9.6: Market Size and CAGR of Various Circulating Biomarker in the North American Liquid Biopsy Market (2026-2035)
  • Table 9.7: Trends and Forecast for the United States Liquid Biopsy Market (2019-2035)
  • Table 9.8: Trends and Forecast for the Mexican Liquid Biopsy Market (2019-2035)
  • Table 9.9: Trends and Forecast for the Canadian Liquid Biopsy Market (2019-2035)
  • Table 10.1: Trends of the European Liquid Biopsy Market (2019-2025)
  • Table 10.2: Forecast for the European Liquid Biopsy Market (2026-2035)
  • Table 10.3: Market Size and CAGR of Various Product in the European Liquid Biopsy Market (2019-2025)
  • Table 10.4: Market Size and CAGR of Various Product in the European Liquid Biopsy Market (2026-2035)
  • Table 10.5: Market Size and CAGR of Various Circulating Biomarker in the European Liquid Biopsy Market (2019-2025)
  • Table 10.6: Market Size and CAGR of Various Circulating Biomarker in the European Liquid Biopsy Market (2026-2035)
  • Table 10.7: Trends and Forecast for the German Liquid Biopsy Market (2019-2035)
  • Table 10.8: Trends and Forecast for the French Liquid Biopsy Market (2019-2035)
  • Table 10.9: Trends and Forecast for the Spanish Liquid Biopsy Market (2019-2035)
  • Table 10.10: Trends and Forecast for the Italian Liquid Biopsy Market (2019-2035)
  • Table 10.11: Trends and Forecast for the United Kingdom Liquid Biopsy Market (2019-2035)
  • Table 11.1: Trends of the APAC Liquid Biopsy Market (2019-2025)
  • Table 11.2: Forecast for the APAC Liquid Biopsy Market (2026-2035)
  • Table 11.3: Market Size and CAGR of Various Product in the APAC Liquid Biopsy Market (2019-2025)
  • Table 11.4: Market Size and CAGR of Various Product in the APAC Liquid Biopsy Market (2026-2035)
  • Table 11.5: Market Size and CAGR of Various Circulating Biomarker in the APAC Liquid Biopsy Market (2019-2025)
  • Table 11.6: Market Size and CAGR of Various Circulating Biomarker in the APAC Liquid Biopsy Market (2026-2035)
  • Table 11.7: Trends and Forecast for the Japanese Liquid Biopsy Market (2019-2035)
  • Table 11.8: Trends and Forecast for the Indian Liquid Biopsy Market (2019-2035)
  • Table 11.9: Trends and Forecast for the Chinese Liquid Biopsy Market (2019-2035)
  • Table 11.10: Trends and Forecast for the South Korean Liquid Biopsy Market (2019-2035)
  • Table 11.11: Trends and Forecast for the Indonesian Liquid Biopsy Market (2019-2035)
  • Table 12.1: Trends of the ROW Liquid Biopsy Market (2019-2025)
  • Table 12.2: Forecast for the ROW Liquid Biopsy Market (2026-2035)
  • Table 12.3: Market Size and CAGR of Various Product in the ROW Liquid Biopsy Market (2019-2025)
  • Table 12.4: Market Size and CAGR of Various Product in the ROW Liquid Biopsy Market (2026-2035)
  • Table 12.5: Market Size and CAGR of Various Circulating Biomarker in the ROW Liquid Biopsy Market (2019-2025)
  • Table 12.6: Market Size and CAGR of Various Circulating Biomarker in the ROW Liquid Biopsy Market (2026-2035)
  • Table 12.7: Trends and Forecast for the Middle Eastern Liquid Biopsy Market (2019-2035)
  • Table 12.8: Trends and Forecast for the South American Liquid Biopsy Market (2019-2035)
  • Table 12.9: Trends and Forecast for the African Liquid Biopsy Market (2019-2035)
  • Table 13.1: Product Mapping of Liquid Biopsy Suppliers Based on Segments
  • Table 13.2: Operational Integration of Liquid Biopsy Manufacturers
  • Table 13.3: Rankings of Suppliers Based on Liquid Biopsy Revenue
  • Table 14.1: New Product Launches by Major Liquid Biopsy Producers (2019-2025)
  • Table 14.2: Certification Acquired by Major Competitor in the Global Liquid Biopsy Market